References
- Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239–252.
- Matsui D, Klein J, Hermann C et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethy1-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991; 50: 294–298.
- Ceci A., Baiardi P, Felisi M et al. The safety and effectiveness ofdeferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330–336.
- Al-Refaie FN, Wonke B, Hoffbrand AV et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethy1-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992; 80: 593–599.
- Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A et al. Li (1,2-dimethy1-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990; 76: 550–553.
- Barman BJA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999; 58: 553–578.
- Agarwal MB, Gupte SS, Vasandani D et al. Efficacy and safety of1,2,-dimethy1-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. J Assoc Physicians India 1991; 39: 669–672.
- Agarwal MB, Gupte SS, Viswanathan C. Long-term assessment ofefficacy and safety of Li, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haemato11992; 82: 460–466.
- Al-Refaie FN, Hershko C, Hoffbrand AV. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224–229.
- Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalas-saemia major patients treated with desferrioxamine and Ll. Br J Haematol 1992; 82: 431–436.
- Pootrakul P, Sirankapracha P, Sankote J. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/ haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305–310.
- Rombos Y, Tzanetea R, Konstantopoulos K. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115–117.
- Hoffbrand AV, Al-Refaie F, Davis B. Long-term trial of deferiprone in Si transfusion-dependent iron overloaded patients. Blood 1998; 91: 295–300.
- Kontoghiorghes G J, Bartlett AN, Hoffbrand AV et al. Long-term trial with the oral iron chelator 1,2-dimethy1-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76: 295–300.
- Olivieri NF, Brittenham GM, Matsui D et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995; 332: 918–922.